<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Unknown</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C2464840-7606-47D9-AE5C-D1A6A69906BC"><gtr:id>C2464840-7606-47D9-AE5C-D1A6A69906BC</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:surname>Ogg</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0701693"><gtr:id>3CDDB5E8-6BB8-4381-8FFE-22D7A9CAB5A5</gtr:id><gtr:title>Proof of concept study of combined allergen immunotherapy and antibiotics for the treatment of chronic atopic dermatitis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701693</gtr:grantReference><gtr:abstractText>Atopic dermatitis (eczema) affects up to 20% of the UK population and is strongly associated with asthma and hayfever. We have shown that a common skin infection, Staphylococcus aureus, can dramatically alter how the body reacts to harmless environmental proteins or allergens. Therefore individuals are more likely to react to an allergen, such as house dust mite, if they encounter it at the same time as staphylococcal infection. Our findings potentially provide a new mechanism for atopic dermatitis and also for atopic and other allergic diseases, including asthma, hayfever and peanut allergy. We will investigate whether by combining anti-bacterial treatment with allergen desensitisation it is possible to improve symptoms in adult individuals with severe atopic dermatitis. We will also take blood samples from study subjects to examine changes in the immune response during treatment. This will give us important insights into how the disease occurs and how we can improve on our results in future clinical trials.
We will present our findings at scientific meetings and through publications, but will also liaise with the public and press whenever appropriate. Dr Graham Ogg has been involved in the presentation of science to the public, for example at the Royal Society Summer Science Exhibition and through the national Public Understanding of Science events and promotes the importance of public engagement in science.</gtr:abstractText><gtr:technicalSummary>We have recently shown that staphylococcal enterotoxin B acts as an adjuvant for allergen-specific Th2 responses in individuals with atopic skin disease. These data provide a novel pathogenesis for atopic disease and link together diverse existing genetic, epidemiological and clinical observations. We aim to translate the findings by testing the hypothesis that combined reduction of S. aureus adjuvant effect and allergen immunotherapy provides clinical benefit for individuals with severe chronic atopic dermatitis. We will undertake a proof of concept clinical evaluation of whether prolonged antibiotic/antiseptic use and allergen immunotherapy improves subjective and objective disease severity scores in adults with severe atopic dermatitis. Furthermore by monitoring changes in allergen-specific humoral and cellular immune responses during successful treatment, we will identify correlates of disease and methods to monitor novel therapeutic strategies. We will use cytokine detection, proliferation and HLA-peptide tetrameric complexes to identify and characterise antigen-specific T cells. The clinical data would translate back to the bench for the design of novel approaches to reduce bacterial adjuvancy, or allergen-specific immune responses and would be used to inform the design of large scale clinical trials to assess differential approaches to the reduction in bacterial load or novel approaches to immunotherapy. Compliant with the Experimental Medicine 2 remit, the proposed interventions are based on existing strategies that have not been studied together in the setting of chronic atopic dermatitis, we would therefore avoid the time and GMP and other development costs and issues (including animal work) required for novel compounds. Although the findings will have particular significance for atopic skin disease, it is also anticipated that the data will be relevant to the associated diseases asthma and allergic rhinitis. In summary, we are aiming to translate our molecular immunology findings into achievable interventions with rapid timelines for clinical benefit to patients.</gtr:technicalSummary><gtr:fund><gtr:end>2013-02-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>309187</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>Biomedical Research centre Oxford</gtr:description><gtr:id>3733F8D6-CD51-4C6B-A94D-45246B5B33D5</gtr:id><gtr:impact>Many outputs as detailed in relevant sections</gtr:impact><gtr:partnerContribution>Access to equipment and individuals</gtr:partnerContribution><gtr:piContribution>We provided many of the samples and technology for analysis of samples using Biomedical Research Centre equipment.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Division of Infection &amp; Immunity</gtr:department><gtr:description>Transduction of TCR</gtr:description><gtr:id>F48EE003-9E7A-437C-9F6E-220CC8F86379</gtr:id><gtr:impact>Still early stages</gtr:impact><gtr:partnerContribution>Help with cloning TCR into primary T cells</gtr:partnerContribution><gtr:piContribution>Provision of T cell clones</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Molecular Haematology Unit</gtr:department><gtr:description>Paul Klenerman VZV</gtr:description><gtr:id>2A81399C-31C3-4A9A-B46E-6B809E510C4D</gtr:id><gtr:impact>Publications and presentations</gtr:impact><gtr:partnerContribution>Access to samples and discussions.</gtr:partnerContribution><gtr:piContribution>Analysis of varicella zoster virus specific immune respoonses after vaccination</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>Andrew McKenzie LMB Cambridge</gtr:description><gtr:id>8C5341FA-5EC3-4DE5-BBF0-866C7F4B1385</gtr:id><gtr:impact>new collaboration</gtr:impact><gtr:partnerContribution>Andrew McKenzie provides knowhow and expertise for access to model skin</gtr:partnerContribution><gtr:piContribution>We are working with Andrew McKenzie to identify nuocytes in human and model skin and relate to clinical disease. we provide knowhow and expertise for access to human skin cells.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>National Science Week</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D50A327B-074A-4A3A-AC7A-F18A2C4F6E9F</gtr:id><gtr:impact>Approximately 150 members of the public attended including many school children.

I get frequent requests for school children to join the group for attachments</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Science Week</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1F76BB85-4950-4F93-9088-FBC118CCBF22</gtr:id><gtr:impact>Approximately 150 members of public attended lectures and displays

I have many school children who wish to have lab attachments</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Skin Foundation Large Research Awards</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>British Skin Foundation</gtr:fundingOrg><gtr:id>F31A029C-78BF-4E2B-BA5E-8A1BDE322A68</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Clinical Research Network (CRN)</gtr:department><gtr:description>Comprehensive Research Network</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>952DBCC0-62B1-471C-B58D-F1B5C7425C8A</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>Oxford Biomedical Research Centre</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Trust</gtr:fundingOrg><gtr:id>68E1C3FF-78E4-4DE3-B09B-837C8BB463D1</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>380000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Experimental Medicine 2</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>654918C6-D5E6-4E4E-8B3A-F4CF60391A34</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Medical Association</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>British Medical Association (BMA)</gtr:fundingOrg><gtr:id>735A2236-F9CE-4787-8382-5618413A95FF</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>62000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Skin Foundation Grant</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>British Skin Foundation</gtr:fundingOrg><gtr:id>19674902-55C6-4FFB-BFAC-958C0520A445</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Use of emulsion PCR and IVTT to identify T cell epitopes</gtr:description><gtr:id>7B946F37-67A9-466D-B63A-E6D701FA3472</gtr:id><gtr:impact>Early days</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>new method to identify T cell epitopes</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>new approaches to investigation and treatment of atopic disease</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>B78D16AD-8F9B-4ECB-A5BD-66A8B462E96B</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>We observed that staphylococcal superantigen facilitates antigen presentation of allergen by epithelial cells. This potentially explains a clinical observation seen in individuals with atopic dermatitis, that flares of disease are often associated with infection. The underlying mechanisms were characterised. I believe this is important for understanding of disease and for the development of new treatment approaches (recent award of MRC Experimental Medicine 2 funding to take this into a proof-of-principle clinical trial).</gtr:description><gtr:id>FA03DEF0-EA98-473A-A2F4-0FCEE0445869</gtr:id><gtr:impact>We hope that this will provide patient benefit</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Idea that combined allergen and anti-bacterial approaches may benefit patients with atopic disease</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2007</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Allergen-specific T cells were derived from human peripheral blood and used to show an interaction with S.aureus. This has lead to the award of an MRC Experimental Medicine 2 grant for a proof of concept clinical trial.</gtr:description><gtr:id>FBF11902-09A6-4275-BDC1-211CDE4A7D39</gtr:id><gtr:impact>many outputs - see relevant sections</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Allergen-specific T cells</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>I was involved in the later stages of HLA peptide tetrameric complex development and refinement of their use (first developed by John Altman, Mark Davis, Andrew McMichael, John Bell et al) and their application to the study of human disease</gtr:description><gtr:id>59741474-0CD6-4C26-8E77-90F48294C5DB</gtr:id><gtr:impact>Vast number of publications have now used the technology</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HLA peptide tetrameric complexes</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53A7ABB6-0CBF-41D8-A00A-279BCE3BB56B"><gtr:id>53A7ABB6-0CBF-41D8-A00A-279BCE3BB56B</gtr:id><gtr:title>Human antimicrobial peptides LL-37 and human ?-defensin-2 reduce viral replication in keratinocytes infected with varicella zoster virus.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/36a38011843727296f99c6a157f048eb"><gtr:id>36a38011843727296f99c6a157f048eb</gtr:id><gtr:otherNames>Crack LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C2B78381-5B70-485F-8B9F-115C43F8EC84"><gtr:id>C2B78381-5B70-485F-8B9F-115C43F8EC84</gtr:id><gtr:title>A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2abd7ea4a2d38b6996263dc56bf14550"><gtr:id>2abd7ea4a2d38b6996263dc56bf14550</gtr:id><gtr:otherNames>Salimi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A06194A3-F1B5-4E8B-8352-AB383D143E3A"><gtr:id>A06194A3-F1B5-4E8B-8352-AB383D143E3A</gtr:id><gtr:title>Molecular characterisation of varicella zoster virus genotypes in Sri Lanka.</gtr:title><gtr:parentPublicationTitle>The Ceylon medical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c4a6dd5de3a715dfe141b2c325690719"><gtr:id>c4a6dd5de3a715dfe141b2c325690719</gtr:id><gtr:otherNames>Lohitharajah J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-0875</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/856C26F7-74F7-48CE-AB7D-58424817FC72"><gtr:id>856C26F7-74F7-48CE-AB7D-58424817FC72</gtr:id><gtr:title>Identification of serotype-specific T cell responses to highly conserved regions of the dengue viruses.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4E8EB477-AB8C-4BE3-892D-4118E9B436C3"><gtr:id>4E8EB477-AB8C-4BE3-892D-4118E9B436C3</gtr:id><gtr:title>Filaggrin-insufficiency in keratinocytes influences responsiveness of allergen-specific T cells to cognate antigen and compounds barrier function deficiency.</gtr:title><gtr:parentPublicationTitle>Clinical immunology (Orlando, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a11eaaa4eac4018346f00a2d8d401fa4"><gtr:id>a11eaaa4eac4018346f00a2d8d401fa4</gtr:id><gtr:otherNames>Marwah I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1521-6616</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B9ED4EB0-EF25-408D-955B-00C851442C3D"><gtr:id>B9ED4EB0-EF25-408D-955B-00C851442C3D</gtr:id><gtr:title>Varicella zoster-specific CD4+Foxp3+ T cells accumulate after cutaneous antigen challenge in humans.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/05d303595cecc95b47227c65d510287e"><gtr:id>05d303595cecc95b47227c65d510287e</gtr:id><gtr:otherNames>Vukmanovic-Stejic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/495E34C5-16FC-4720-AE49-0353A9505BC9"><gtr:id>495E34C5-16FC-4720-AE49-0353A9505BC9</gtr:id><gtr:title>Pathogenesis of severe dengue infection.</gtr:title><gtr:parentPublicationTitle>The Ceylon medical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-0875</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F0F38B27-F8EE-404F-ADCA-6F2BE7794D2B"><gtr:id>F0F38B27-F8EE-404F-ADCA-6F2BE7794D2B</gtr:id><gtr:title>Identification of an immunodominant region of the major house dust mite allergen Der p 2 presented by common human leucocyte antigen alleles.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/36a38011843727296f99c6a157f048eb"><gtr:id>36a38011843727296f99c6a157f048eb</gtr:id><gtr:otherNames>Crack LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7D0521AD-53B2-4986-B5F1-0047A44674D6"><gtr:id>7D0521AD-53B2-4986-B5F1-0047A44674D6</gtr:id><gtr:title>IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion.</gtr:title><gtr:parentPublicationTitle>Experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/78cc0e45655711af82820a4e2ca0763f"><gtr:id>78cc0e45655711af82820a4e2ca0763f</gtr:id><gtr:otherNames>Gutowska-Owsiak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0906-6705</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FBAF49DB-B35C-4692-A704-0BC594B31649"><gtr:id>FBAF49DB-B35C-4692-A704-0BC594B31649</gtr:id><gtr:title>Histamine exerts multiple effects on expression of genes associated with epidermal barrier function.</gtr:title><gtr:parentPublicationTitle>Journal of investigational allergology &amp; clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/78cc0e45655711af82820a4e2ca0763f"><gtr:id>78cc0e45655711af82820a4e2ca0763f</gtr:id><gtr:otherNames>Gutowska-Owsiak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1018-9068</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5BB05578-F17B-44D2-96FE-DCC561DE7273"><gtr:id>5BB05578-F17B-44D2-96FE-DCC561DE7273</gtr:id><gtr:title>IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/347E8833-14F7-424C-8B19-A18B2A9DBCBC"><gtr:id>347E8833-14F7-424C-8B19-A18B2A9DBCBC</gtr:id><gtr:title>Penicillin to prevent recurrent leg cellulitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c8cbd8e168571c0a67a1a4ebaa06aedc"><gtr:id>c8cbd8e168571c0a67a1a4ebaa06aedc</gtr:id><gtr:otherNames>Thomas KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/98CB2A53-B0FD-4065-AFFA-5536DD65C1A6"><gtr:id>98CB2A53-B0FD-4065-AFFA-5536DD65C1A6</gtr:id><gtr:title>Phenotypic analysis of perennial airborne allergen-specific CD4+ T cells in atopic and non-atopic individuals.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/36a38011843727296f99c6a157f048eb"><gtr:id>36a38011843727296f99c6a157f048eb</gtr:id><gtr:otherNames>Crack LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7567428D-FBAF-435B-9EE3-D4B6D578E5D6"><gtr:id>7567428D-FBAF-435B-9EE3-D4B6D578E5D6</gtr:id><gtr:title>Natural killer cells during primary varicella zoster virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BCEF9C29-CE8D-4CCC-B887-D344D1731086"><gtr:id>BCEF9C29-CE8D-4CCC-B887-D344D1731086</gtr:id><gtr:title>Suppression of virus specific immune responses by IL-10 in acute dengue infection.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3EEFFBF5-754B-433E-9B1D-97F633CEA521"><gtr:id>3EEFFBF5-754B-433E-9B1D-97F633CEA521</gtr:id><gtr:title>UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4b92248aa9aa776b4e5f582b97a1c018"><gtr:id>4b92248aa9aa776b4e5f582b97a1c018</gtr:id><gtr:otherNames>Craig FF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/998D35E3-E2B0-4787-BC5F-43E1A6F295BF"><gtr:id>998D35E3-E2B0-4787-BC5F-43E1A6F295BF</gtr:id><gtr:title>Frequencies of circulating allergen-specific T cells temporally associate with longitudinal changes in severity of cutaneous atopic disease.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db7a2dff8c69b5c21428b73c305de53e"><gtr:id>db7a2dff8c69b5c21428b73c305de53e</gtr:id><gtr:otherNames>McPherson T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EFF0F42B-8CF2-48ED-8C3E-33064607A805"><gtr:id>EFF0F42B-8CF2-48ED-8C3E-33064607A805</gtr:id><gtr:title>Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/972bcd649809975a6ae6579df5d505cb"><gtr:id>972bcd649809975a6ae6579df5d505cb</gtr:id><gtr:otherNames>Xue L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1464D09E-BA7F-4DD3-8E56-3541D078ABD5"><gtr:id>1464D09E-BA7F-4DD3-8E56-3541D078ABD5</gtr:id><gtr:title>MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/88f7632d46b6836b8594e227c55d3fc9"><gtr:id>88f7632d46b6836b8594e227c55d3fc9</gtr:id><gtr:otherNames>Oliphant CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3123F00A-0F3D-49D7-B32A-41CF1BCBA4D8"><gtr:id>3123F00A-0F3D-49D7-B32A-41CF1BCBA4D8</gtr:id><gtr:title>HLA class I and class II associations in dengue viral infections in a Sri Lankan population.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/50899AA9-E333-4C03-BECD-0AF30D66E6A6"><gtr:id>50899AA9-E333-4C03-BECD-0AF30D66E6A6</gtr:id><gtr:title>T cell responses in dengue viral infections.</gtr:title><gtr:parentPublicationTitle>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1386-6532</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EFFF5B44-8EF4-4282-98FA-D3A981C45D2D"><gtr:id>EFFF5B44-8EF4-4282-98FA-D3A981C45D2D</gtr:id><gtr:title>The epidermis as an adjuvant.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/78cc0e45655711af82820a4e2ca0763f"><gtr:id>78cc0e45655711af82820a4e2ca0763f</gtr:id><gtr:otherNames>Gutowska-Owsiak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5E71832A-229C-4E38-AA3F-CDC549309C7F"><gtr:id>5E71832A-229C-4E38-AA3F-CDC549309C7F</gtr:id><gtr:title>Histamine enhances keratinocyte-mediated resolution of inflammation by promoting wound healing and response to infection.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/78cc0e45655711af82820a4e2ca0763f"><gtr:id>78cc0e45655711af82820a4e2ca0763f</gtr:id><gtr:otherNames>Gutowska-Owsiak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40A587E1-14B6-4F9C-9C61-94DAC8AFAA1C"><gtr:id>40A587E1-14B6-4F9C-9C61-94DAC8AFAA1C</gtr:id><gtr:title>Cellular and cytokine correlates of severe dengue infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C18E9AA9-B658-4DF3-B416-1F6F620F281A"><gtr:id>C18E9AA9-B658-4DF3-B416-1F6F620F281A</gtr:id><gtr:title>Linking genotype to phenotype on beads: high throughput selection of peptides with biological function.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/63dd7815b106ce172e0bae9d5d1fe643"><gtr:id>63dd7815b106ce172e0bae9d5d1fe643</gtr:id><gtr:otherNames>Huang LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/17A8DE4B-4862-4C38-840D-D74B27E7CD67"><gtr:id>17A8DE4B-4862-4C38-840D-D74B27E7CD67</gtr:id><gtr:title>Serum IL-10 as a marker of severe dengue infection.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b646fe711bb87d5789a9438f00cb75be"><gtr:id>b646fe711bb87d5789a9438f00cb75be</gtr:id><gtr:otherNames>Malavige GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C48EDB3F-37D9-47B6-B23C-1743D6A47649"><gtr:id>C48EDB3F-37D9-47B6-B23C-1743D6A47649</gtr:id><gtr:title>Cytokine regulation of the epidermal barrier.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/78cc0e45655711af82820a4e2ca0763f"><gtr:id>78cc0e45655711af82820a4e2ca0763f</gtr:id><gtr:otherNames>Gutowska-Owsiak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FB08E64A-3E6E-44C7-8599-41DA3EAF76F8"><gtr:id>FB08E64A-3E6E-44C7-8599-41DA3EAF76F8</gtr:id><gtr:title>Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/78cc0e45655711af82820a4e2ca0763f"><gtr:id>78cc0e45655711af82820a4e2ca0763f</gtr:id><gtr:otherNames>Gutowska-Owsiak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1142A3E1-790F-4E39-B0BA-D67035011989"><gtr:id>1142A3E1-790F-4E39-B0BA-D67035011989</gtr:id><gtr:title>Evaluation of the WHO revised criteria for classification of clinical disease severity in acute adult dengue infection.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/87abb607a6d8c07e3ff22921a3deb991"><gtr:id>87abb607a6d8c07e3ff22921a3deb991</gtr:id><gtr:otherNames>Jayaratne SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B80D6610-4517-429B-AE0E-0759E8C04784"><gtr:id>B80D6610-4517-429B-AE0E-0759E8C04784</gtr:id><gtr:title>Filaggrin-insufficiency in keratinocytes influences responsiveness of allergen-specific T cells to cognate antigen and compounds barrier function deficiency.</gtr:title><gtr:parentPublicationTitle>Clinical immunology (Orlando, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a11eaaa4eac4018346f00a2d8d401fa4"><gtr:id>a11eaaa4eac4018346f00a2d8d401fa4</gtr:id><gtr:otherNames>Marwah I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1521-6616</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C86EA98E-6EF1-4B6D-B0F3-6DD518688C2E"><gtr:id>C86EA98E-6EF1-4B6D-B0F3-6DD518688C2E</gtr:id><gtr:title>Rapid effector function of circulating CD4+ T cells specific for immunodominant regions of the conserved serine/threonine kinase found in Streptococcus pneumoniae (StkP) in healthy adults.</gtr:title><gtr:parentPublicationTitle>FEMS immunology and medical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/31d0e3a7e251ddfd1290bf38f51937a3"><gtr:id>31d0e3a7e251ddfd1290bf38f51937a3</gtr:id><gtr:otherNames>Aslam A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0928-8244</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF90A58E-701E-4422-8BFC-41ACADDD2266"><gtr:id>BF90A58E-701E-4422-8BFC-41ACADDD2266</gtr:id><gtr:title>Leukotriene E4 activates human Th2 cells for exaggerated proinflammatory cytokine production in response to prostaglandin D2.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/972bcd649809975a6ae6579df5d505cb"><gtr:id>972bcd649809975a6ae6579df5d505cb</gtr:id><gtr:otherNames>Xue L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D95B775-E5E6-4B7B-B380-B703F8C1D55B"><gtr:id>0D95B775-E5E6-4B7B-B380-B703F8C1D55B</gtr:id><gtr:title>Characteristics of Staphylococcus aureus colonization in patients with atopic dermatitis in Sri Lanka.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb88fe071003b8e2686be4cbad92fca9"><gtr:id>bb88fe071003b8e2686be4cbad92fca9</gtr:id><gtr:otherNames>Gomes PL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53FFD786-EBE1-4CD2-BB60-1096F7FA3454"><gtr:id>53FFD786-EBE1-4CD2-BB60-1096F7FA3454</gtr:id><gtr:title>The histamine-synthesizing enzyme histidine decarboxylase is upregulated by keratinocytes in atopic skin.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/78cc0e45655711af82820a4e2ca0763f"><gtr:id>78cc0e45655711af82820a4e2ca0763f</gtr:id><gtr:otherNames>Gutowska-Owsiak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6F27FA11-5AE6-496F-8C34-CD512ED43D80"><gtr:id>6F27FA11-5AE6-496F-8C34-CD512ED43D80</gtr:id><gtr:title>Combinatorial HLA-peptide bead libraries for high throughput identification of CD8? T cell specificity.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fa6b6c24080c1135d3653d8e343c7a89"><gtr:id>fa6b6c24080c1135d3653d8e343c7a89</gtr:id><gtr:otherNames>Pan X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6A956B40-0C72-4F1B-958D-9AD188B1E51A"><gtr:id>6A956B40-0C72-4F1B-958D-9AD188B1E51A</gtr:id><gtr:title>Filaggrin null mutations associate with increased frequencies of allergen-specific CD4+ T-helper 2 cells in patients with atopic eczema.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db7a2dff8c69b5c21428b73c305de53e"><gtr:id>db7a2dff8c69b5c21428b73c305de53e</gtr:id><gtr:otherNames>McPherson T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1441008B-6C87-4934-9156-C67E602C294B"><gtr:id>1441008B-6C87-4934-9156-C67E602C294B</gtr:id><gtr:title>Common filaggrin null alleles are not associated with hymenoptera venom allergy in Europeans.</gtr:title><gtr:parentPublicationTitle>International archives of allergy and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/31d0e3a7e251ddfd1290bf38f51937a3"><gtr:id>31d0e3a7e251ddfd1290bf38f51937a3</gtr:id><gtr:otherNames>Aslam A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1018-2438</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701693</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7EE9741E-CF94-420A-B0AB-A7811523CF2C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Skin</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>